China SXT Pharmaceuticals Raises $760,000 in Registered Share Offering

China SXT Pharmaceuticals ( (SXTC) ) has provided an update.

On April 7, 2026, China SXT Pharmaceuticals entered into a securities purchase agreement with investors to sell 2,000,000 Class A ordinary shares in a registered offering under its effective shelf registration. The shares, priced to yield expected gross proceeds of about $760,000, are being issued pursuant to a Form F-3 registration statement and related prospectus supplement filed with the U.S. Securities and Exchange Commission.

The offering is expected to close on April 9, 2026, subject to customary conditions, with the company planning to use the net proceeds for general corporate purposes. The relatively modest equity raise provides incremental liquidity while slightly diluting existing shareholders, and it underscores China SXT’s continued reliance on U.S. capital markets to fund its operations and strategic flexibility.

More about China SXT Pharmaceuticals

China SXT Pharmaceuticals, Inc., based in Taizhou, Jiangsu, is a China-focused drugmaker whose business centers on the development and sale of pharmaceutical products. The company is listed in the U.S. as a foreign private issuer, giving it access to international capital markets to support its corporate and operational needs.

Average Trading Volume: 298,390

Technical Sentiment Signal: Sell

Current Market Cap: $2.16M

See more insights into SXTC stock on TipRanks’ Stock Analysis page.